Stock Market Today: Stocks Waver Ahead of Busy Earnings Week
While the major market indexes made modest moves Monday, Prometheus Biosciences popped on M&A news.
It was a slow start to the week for stocks as investors took in mixed quarterly results from a handful of financial sector names. The real fireworks kick off later this week when first-quarter earnings season gets rolling.
Drilling down into this morning's quarterly results, Charles Schwab (SCHW, +3.9%) said earnings were up 21% year-over-year to 93 cents per share, beating the consensus estimate. Revenue rose 10% to $5.1 billion, but fell short of expectations. Although "investor sentiment remained bearish – especially following the onset of the banking industry turmoil in early March ... clients opened over 1 million new brokerage accounts and entrusted us with $132 billion of core net new assets," said Schwab CEO Walt Bettinger.
State Street (STT, -9.2%) was another financial firm that reported Q1 earnings ahead of the open. STT said earnings fell 3.2% to $1.52 per share, while revenue was mostly flat at $3.1 billion. Both figures missed consensus estimates due in part to lower fee revenue and a $29 million provision tied to a $1 billion deposit made to First Republic (FRC, +0.2%) to shore up the embattled regional bank's liquidity.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Looking ahead, Netflix (NFLX, -1.8%) and Tesla (TSLA, +1.1%) are just two of the high-profile names on this week's earnings calendar, with results from the streaming giant and electric vehicle maker due out tomorrow and Wednesday, respectively.
In non-earning news, Prometheus Biosciences (RXDX) surged 69.7% on news that blue chip stock Merck (MRK, -0.3%) will purchase the biotech for roughly $10.8 billion in cash. The "lead asset of Prometheus (PRA023) is an antibody that binds TL1A, a target associated with both intestinal inflammation and fibrosis," says BofA Securities analyst Geoff Meacham. "We see the deal as a strategic positive and another step in the right direction to diversify Keytruda concentration risk."
At the close, the Dow Jones Industrial Average was up 0.3% at 33,987, the S&P 500 had gained 0.3% at 4,151, and the Nasdaq Composite was 0.3% higher at 12,157.
The biggest U.S. cities with the cheapest rent
Last Wednesday's consumer price index (CPI) report is still fresh on investors' minds, particularly as the next Fed meeting creeps closer. "Inflation is continuing to come down," says Kevin Simpson, founder and chief investment officer of investment advisory firm Capital Wealth Planning. "Food prices were flat for the month and showed a monthly decline of 0.3% in the food at home category. Energy prices also declined by 3.5% for the month, including gasoline, which dropped 4.6%." But shelter, which makes up roughly a third of the overall index, remained sticky, rising 8.2% year-over-year, he adds.
High levels of inflation have certainly made the most expensive cities in the U.S. that much pricier, but not all areas of the country suffer from such excessive costs. The 10 biggest U.S. cities with the cheapest apartment rents, for instance, all offer rental options at rates well below the national average. And some of the metro areas sporting the cheapest apartment rents also happen to be among the cheapest U.S. cities to live in.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

With over a decade of experience writing about the stock market, Karee Venema is the senior investing editor at Kiplinger.com. She joined the publication in April 2021 after 10 years of working as an investing writer and columnist at a local investment research firm. In her previous role, Karee focused primarily on options trading, as well as technical, fundamental and sentiment analysis.
-
Is Mechanical Breakdown Insurance Better Than an Extended Car Warranty?More insurers are starting to offer mechanical breakdown insurance to new car owners. What is it and should you buy it?
-
What to Do When You Bank Lowers Your APYWhy banks lower APYs, options you can explore when it happens and whether more rate cuts are on the horizon.
-
Forget Financial Forecasts: Focus on These 3 Goals for SuccessWe know the economy is unpredictable and markets will do what they do, no matter who predicts what. Here's how to focus on what you can control.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
Stocks Extend Losing Streak After Fed Minutes: Stock Market TodayThe Santa Claus Rally is officially at risk after the S&P 500's third straight loss.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
Santa Claus Rally at Risk as Tech Stocks Slump: Stock Market TodayThe Nasdaq Composite and Dow Jones Industrial Average led today's declines as investors took profits on high-flying tech stocks.
-
Nasdaq Sinks 418 Points as Tech Chills: Stock Market TodayInvestors, traders and speculators are growing cooler to the AI revolution as winter approaches.
-
Stocks Slip to Start Fed Week: Stock Market TodayWhile a rate cut is widely expected this week, uncertainty is building around the Fed's future plans for monetary policy.
-
Stocks Keep Climbing as Fed Meeting Nears: Stock Market TodayA stale inflation report and improving consumer sentiment did little to shift expectations for a rate cut next week.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.